Bisphosphonates and chronic kidney disease
WebIn summary, it has been demonstrated that bisphosphonate therapy has a potential renal toxicity for patients with moderate to severe chronic kidney disease, and the research … WebMay 20, 2010 · Bisphosphonates, which are excreted via the kidneys, may accumulate in patients with diminished renal function, and …
Bisphosphonates and chronic kidney disease
Did you know?
WebThe results of work package 1 suggested a 12% excess risk of chronic kidney disease progression among users of bisphosphonates compared with matched non-users. The observed effect appeared stronger in those exposed to higher doses. Sensitivity analyses confirmed the robustness of these findings. WebBisphosphonates are eliminated from the human body by the kidney. Renal clearance is both by glomerular filtration and proximal tubular secretion. Bisphosphonates given rapidly in high doses in animal models have induced a variety of adverse renal effects, from glomerular sclerosis to acute tubular necrosis.
WebApr 15, 2024 · While the use of bisphosphonates in patients with severe renal disease is usually avoided due to long-term adverse events concerning bone-turnover effects, their effect in a potentially life-threatening disease like CP is promising. ... The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: a ... WebAug 4, 2024 · Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif. 2010;29(3):293-299. Crossref. …
WebNephrotoxic medications should be avoided in patients with chronic kidney disease, and the consultation should include the patient’s glomerular filtration rate. ... A history of … WebMedication-related osteonecrosis of the jaw is a serious complication associated with the use of bisphosphonates and other antiresorptive agents or antiangiogenic cancer treatments ( Table 3). 9,...
WebMar 1, 2024 · Bisphosphonates were associated with a 12% excess risk of chronic kidney disease progression in participants with stage 3B+ chronic kidney disease. No other …
WebAt present, only bisphosphonates (BPs), currently considered the drug of choice for the prevention and treatment of osteoporosis, could have this potential. 50 – 52 In a mouse model of glucocorticoid-induced osteoporosis, denosumab, a human monoclonal antibody targeting RANKL, reduced the progression of atherosclerosis. 41 Moreover, a more … bruce mcgibbon mdWebAug 1, 2013 · Postmarketing Evidence of the Effect of Bisphosphonates on Renal Function. Clinical trials have the advantage that all safety outcomes are recorded, follow-up is good, and the risks of particular adverse events can be calculated. ... (such as chronic diabetic renal disease, chronic pulmonary obstructive disease, or hypertension) ... bruce mcfarland obituaryWebBisphosphonates are the first-line treatment for preventing fractures in osteoporosis patients. However, their use is contraindicated or to be used with caution in chronic … evusheld observation periodWebApr 11, 2024 · Based on the pathophysiology, the treatment of osteoporosis can be divided into 2 categories: antiresorptive and anabolic. For most kidney transplant recipients (KTRs) with high turnover bone disease, treatment involving antiresorptives (eg, bisphosphonates, estrogen, and denosumab) reduces bone turnover through distinct mechanisms [[1], [2], … bruce mcewen and eliot stellar in 1993WebBisphosphonates are effective in the prevention and treatment of osteoporosis but current recommendations limit their use in patients with renal impairment because of concern regarding the safety profile of these agents in the setting of reduced renal function. bruce mcewen new york timesWebJun 1, 2007 · The case for bisphosphonates in patients with renal disease In the non-renal population, convincing evidence exists to show that bisphosphonates can … evusheld orderingevusheld patient handout